Certara (NASDAQ:CERT) Sets New 12-Month Low – Should You Sell?

Certara, Inc. (NASDAQ:CERT) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.46 and last traded at $9.52, with a volume of 13945 shares trading hands. The stock had previously closed at $9.55.

Analysts Set New Price Targets

CERT has been the topic of a number of recent analyst reports. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Finally, Barclays dropped their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Trading Up 6.0 %

The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -51.80, a price-to-earnings-growth ratio of 5.00 and a beta of 1.51. The company’s 50-day moving average price is $10.79 and its 200-day moving average price is $13.22. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same period in the previous year, the firm posted $0.06 EPS. Certara’s revenue was up 10.7% compared to the same quarter last year. Equities analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 33.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by corporate insiders.

Institutional Trading of Certara

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares during the period. Jane Street Group LLC increased its holdings in shares of Certara by 2.6% during the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after buying an additional 3,732 shares during the last quarter. State Street Corp raised its position in shares of Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after buying an additional 122,411 shares during the period. Petrus Trust Company LTA acquired a new position in Certara in the third quarter valued at approximately $994,000. Finally, Paloma Partners Management Co purchased a new position in Certara in the third quarter worth approximately $413,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.